References
- Chesher D. 2008. Evaluating assay precision. Clin Biochem Rev. 29(Suppl 1):S23–S26.
- FDA. 2023. FDA Revised Botanical Drug Development, Guidance for Industry [accessed April 4, 2023]. https://www.fda.gov/media/93113/download.
- HEK-BlueTM hTLR2-TLR1 cells. 2023. SEAP reporter 293 cells expressing the human TLR2 and TLR1 genes. Catalog code: hkb-htlr21 [accessed May 16, 2023]. https://www.invivogen.com/sites/default/files/invivogen/products/files/hek-blue_htlr2-tlr1_tds.pdf.
- HKEB. 2023. Heat Killed E.coli 0111:B4 – TLR2 & TLR4 agonist. Catalog # tlrl-hkeb2 [accessed May 16, 2023]. https://www.invivogen.com/sites/default/files/invivogen/products/files/hkeb_tds.pdf.
- Huh J, Zhang J, Hauerová R, Lee J, Haider S, Wang M, Hauer T, Khan IA, Chittiboyina AG, Pugh ND. 2022. Utility of fatty acid profile and in vitro immune cell activation for chemical and biological standardization of Arthrospira/Limnospira. Sci Rep. 12(1):15657. doi: 10.1038/s41598-022-19590-x.
- Krause E, Yuan Y, Hajirahimkhan A, Dong H, Dietz BM, Nikolic D, Pauli GF, Bolton JL, van Breemen RB. 2014. Biological and chemical standardization of a hop (Humulus lupulus) botanical dietary supplement. Biomed Chromatogr. 28(6):729–734. doi: 10.1002/bmc.3177.
- Mire-Sluis AR. 2001. Progress in the use of biological assays during the development of biotechnology products. Pharm Res. 18(9):1239–1246. doi: 10.1023/a:1013067424248.
- Nielsen CH, Balachandran P, Christensen O, Pugh ND, Tamta H, Sufka KJ, Wu X, Walsted A, Schjørring-Thyssen M, Enevold C, et al. 2010. Enhancement of natural killer cell activity in healthy subjects by Immulina®, a Spirulina extract enriched for Braun-type lipoproteins. Planta Med. 76(16):1802–1808. doi: 10.1055/s-0030-1250043.
- Novitsky TJ, Schmidt-Gengenbach J, Remillard JF. 1986. Factors affecting recovery of endotoxin adsorbed to container surfaces. PDA J Pharm Sci Technol. 40(6):284–286.
- Pam3CSK4. 2023. Synthetic triacylated lipoprotein; TLR2/TLR1 ligand. Catalog code: tlrl-pms [accessed May 16, 2023]. https://www.invivogen.com/sites/default/files/invivogen/products/files/pam3csk4_tds.pdf.
- Piersen CE, Booth NL, Sun Y, Liang W, Burdette JE, van Breemen RB, Geller SE, Gu C, Banuvar S, Shulman LP, et al. 2004. Chemical and biological characterization and clinical evaluation of botanical dietary supplements: a phase I red clover extract as a model. Curr Med Chem. 11(11):1361–1374. doi: 10.2174/0929867043365134.
- Piluso L, Martinez M. 1999. Resolving liposomal inhibition of quantitative LAL methods. PDA J Pharm Sci Technol. 53(5):260–263.
- Shipkowski KA, Betz JM, Birnbaum LS, Bucher JR, Coates PM, Hopp DC, MacKay D, Oketch-Rabah H, Walker NJ, Welch C, et al. 2018. Naturally complex: perspectives and challenges associated with botanical dietary supplement safety assessment. Food Chem Toxicol. 118:963–971. doi: 10.1016/j.fct.2018.04.007.
- United States Pharmacopeia Method #1225. 2021. Validation of compendial procedures [accessed May 26, 2023]. https://online.uspnf.com/uspnf/document/1_GUID-E2C6F9E8-EA71-4B72-A7BA-76ABD5E72964_4_en-US.
- Wu C, Lee S-L, Taylor C, Li J, Chan Y-M, Agarwal R, Temple R, Throckmorton D, Tyner K. 2020. Scientific and regulatory approach to botanical drug development: a US FDA perspective. J Nat Prod. 83(2):552–562. doi: 10.1021/acs.jnatprod.9b00949.